Breaking News
LAST CHANCE for Cyber Monday SALE: Up to 54% off InvestingPro! Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Explainer-How does AstraZeneca's vaccine compare with Pfizer-BioNTech?

Stock MarketsDec 30, 2020 08:45PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. A medical worker shows a dose of the Pfizer-BioNTech COVID-19 vaccine at the Regional Military Specialty Hospital in San Nicolas de los Garza, on the outskirts of Monterrey 2/2

By John Miller

ZURICH (Reuters) - Britain on Wednesday became the first country to approve AstraZeneca (NASDAQ:AZN) and Oxford University's home-grown UK COVID-19 vaccine, adding an easy-to-manage shot to the arsenal of a nation desperate for pandemic relief.

Even so, scientists - and regulators in Europe, following the Brexit divorce - are sceptical, given confusion over trial results earlier that left experts questioning the robustness of the data.

HOW DOES THE ASTRAZENECA SHOT'S EFFICACY STACK UP TO OTHERS'?

The AstraZeneca/Oxford vaccine's efficacy in preventing symptomatic infections was 70.4%, according to interim data, after 30 of 5,807 people who got the two-dose vaccine developed COVID-19, compared with 101 of 5,829 people who got a placebo.

That compares with the 95% efficacy of the two-shot vaccine from Pfizer/BioNTech, the other vaccine approved in Britain.

While efficacy with any dose after one dose was pegged at 52.7%, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) regulator also said an "exploratory analysis" of trial participants who got one full dose showed efficacy of 73% from 22 days after the first shot.

The UK regulator recommends a booster shot four to 12 weeks after the first dose, because up to 80% efficacy was reached with a three-month interval between shots, an official involved in the MHRA approval said.

"The first dose efficacy gives an indication of protection for a short period between the two doses, the second dose strengthens the immune response and is expected to provide a more durable immune response," the University of Oxford, AstraZeneca's partner, said.

Confusion over efficacy emerged after interim late-stage trial results announced in late November when AstraZeneca acknowledged that people in its clinical trial accidentally got different doses.

Those who received a half dose of the vaccine, followed by a full dose, were shown to have 90% protection, the company said initially, while two full doses offered only 62% protection.

Now, however, the MHRA said the half-dose regimen's results were not borne out in analysis.

"It's all much more confusing because mistakes have been made, genuinely," one European Medicines Agency (EMA) official told Reuters. "Mistakes that resulted in clinical data that was much more complex to interpret than Moderna (NASDAQ:MRNA)'s and Pfizer (NYSE:PFE)'s. And on top of that the efficacy is lower."

WHAT ARE THE OTHER DIFFERENCES?

Technology, price and storage.

The AstraZeneca shot is a "viral vector vaccine", where a specially engineered virus that normally causes chimpanzees to get the common cold delivers genetic instructions to human cells to make the spike protein jutting out from the new coronavirus's surface.

The Pfizer/BioNTech and Moderna vaccines use a new technology which packs messenger RNA (mRNA) inside tiny fat droplets to instruct cells to make the spike protein.

AstraZeneca pledged the vaccine would cost just a few dollars per dose and be sold without making a profit, whereas Pfizer's vaccine costs $18.40-$19.50 per dose.

A separate mRNA vaccine from Moderna, approved in the United States, costs up to $37.

The AstraZeneca shot does not require deep freezing at minus 70 degrees like the mRNA vaccine from Pfizer and its German partner, BioNTech, and has already been produced by the millions of doses.

It can be kept in a standard refrigerator for six months.

It is also cheaper to make, bringing hope to developing countries largely left out of the early vaccine haul.

NOW THAT THE UK HAS APPROVED THE VACCINE, WILL OTHER GOVERNMENTS FOLLOW?

When Britain signed off on Pfizer/BioNTech's vaccine in early December, that pressured regulators elsewhere, and the United States and Europe followed in short order.

Moderna's similar mRNA vaccine has also received U.S. approval.

Britain's move now to back AstraZeneca's shot prioritises getting as many people inoculated quickly, before all the answers about efficacy and optimal dosing are in.

Absent safety concerns, British regulators may be making a trade-off between waiting for perfection and making do with what they have.

"A swift emergency approval implies taking the risks of a lower (or) shorter efficacy than may be reached with mRNA vaccines," said Claire-Anne Siegrist, vaccinology and immunology head at Geneva's University Hospitals.

While an EMA official said this week the shot is unlikely to be approved before the end of January, a top German vaccine official said on Wednesday he still expected a "quick decision" by Europe since its rolling review process is well advanced.

The EU drug watchdog is carrying out a review for a conditional market approval, rather than the UK's speedier emergency use approval.

India's drug regulator is also discussing emergency approval of the AstraZeneca vaccine, being made in partnership with the Serum Institute of India.

WHO WILL GET WHICH VACCINE?

England's National Health Service will not give people a choice of vaccine.

But with several now available, countries need to decide who should get which vaccine, as some people may prefer the shots with higher efficacy.

Experts said the differences between the efficacy rates are significant, prompting tough choices.

"In countries where both the mRNA and the AstraZeneca vaccines would be available, whom do you decide to give the less effective vaccine?" Siegrist said.

Thomas Mertens, head of STIKO, Germany's expert panel on vaccine use, told Reuters that his group plans to address this issue "in the near future" as it hopes to tailor a strategy that makes the biggest impact with limited supplies.

Some experts, however, said that choice may be a luxury countries cannot afford.

    "At this juncture, we don't have vaccine in sufficient quantities to reach all those who need it," said Thomas Klimkait, a University of Basel professor and researcher who is working on a Swiss SARS-CoV-2 vaccine project.

"I would say at this moment that every vaccine with relatively good efficacy - that means, at least 60 or 70% - should be put to use, when it has an appropriate safety profile."

Explainer-How does AstraZeneca's vaccine compare with Pfizer-BioNTech?
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Roger Miller
Roger Miller Dec 30, 2020 10:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Politicians and bureaucrats deciding on who is more deserving or valuable sounds a bit dystopian.  Why not make it random, it is till much better than no vaccine?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email